Should I buy Summit Therapeutics stock in 2025?

Why trust HelloSafe?

At HelloSafe, our experts have been closely tracking the performance of Summit Therapeutics for over three years. Every month, tens of thousands of users in Singapore rely on us to provide clear market insights and highlight the best investment opportunities. Our analyses are offered purely for informational purposes and do not constitute investment advice. In line with our ethical charter, we have never been, and will never be, compensated by Summit Therapeutics.

What is Summit Therapeutics?

How much is Summit Therapeutics stock?

The price of Summit Therapeutics stock is rising this week. As of now, SMMT is trading at US$24.65, reflecting a 1.48% gain over the past 24 hours, while its weekly movement shows a slight decrease of 0.08%. The company holds a market capitalization of US$18.31 billion and maintains a robust average daily trading volume of 4.04 million shares over the last three months.

Summit Therapeutics currently does not have a P/E ratio or dividend yield, and its beta stands at -0.95, suggesting a negative correlation with the broader market.

Given its recent strong momentum but historically high volatility, investors in Singapore should closely monitor market developments when considering this biotechnology stock.

Our full analysis on Summit Therapeutics stock

We have conducted an in-depth review of Summit Therapeutics' latest financial results alongside a comprehensive assessment of its stock performance over the past three years. Our proprietary multi-factor models, incorporating both technical signals and core financial data—alongside competitive and sectoral analyses—underscore a dynamic opportunity emerging for this ambitious biopharma leader. So, why might Summit Therapeutics once again become a strategic entry point into the global oncology innovation landscape in 2025?

Recent Performance and Market Context

Stock Momentum and Price Evolution

Summit Therapeutics (NASDAQ: SMMT) has delivered a stellar performance, positioning itself firmly in the market spotlight. As of May 9, 2025, SMMT is trading at $24.65, a figure that represents an extraordinary 396.98% appreciation over the past twelve months, and a 38.13% rise year-to-date. Volatility has accompanied this ascent—evidenced by a 52-week range from $2.10 to $36.91—but the positive bias is unmistakable.

Key price milestones further reinforce this trajectory. Despite a brief pullback from its recent high of $29.99, the current consolidation above the 50-day ($21.70) and 200-day ($19.19) moving averages is indicative of sustained bullish momentum. The average daily volume—at over 4 million shares—confirms robust market engagement and confidence in Summit’s story.

Positive Catalysts and Market Drivers

Several major positive events have propelled SMMT throughout 2024 and into 2025:

• HARMONi-6 Phase III Success: The demonstration of statistically superior progression-free survival for ivonescimab plus chemotherapy, relative to best-in-class peers, has validated Summit’s pipeline approach.
• Regulatory Milestones: The approval of ivonescimab in China for a second NSCLC indication is a watershed, both as a commercial validation and as a licensing platform.
• Strategic Partnerships: Expanded collaborations with institutions such as MD Anderson, Pfizer, Memorial Sloan Kettering, and Dana Farber considerably de-risk the development landscape, providing both global reach and technical synergies.

From a macro perspective, the biopharma sector continues to benefit from secular tailwinds: growing oncology prevalence, accelerated regulatory pathways for novel therapies, and robust capital markets support. These factors amplify Summit’s relevance, especially for Singapore investors attuned to global innovation flows.

Technical Analysis

Momentum and Indicator Profile

Summit is consolidating above both its 50-day and 200-day moving averages, with the current price at $24.65 comfortably above these key technical benchmarks. The near-term Relative Strength Index (RSI) suggests heightened buying interest—hovering near overbought territory—which typically validates underlying strength, particularly given the healthy consolidation after a 48.14% surge in the past month.

• RSI (14-day): Approaching 70, signaling strong momentum but not yet an exhaustion move; this is frequently a hallmark of a robust uptrend rather than a topping process.
• MACD: (Not explicitly reported but inferred from price action above MA) likely supportive given trend alignment.
• Support and Resistance: $21.70 (50-day MA) acts as strong support, while a move through $29.99 may unleash further upside.

The technical structure in the short to medium term appears decisively bullish, favoring accumulation on pullbacks. The characteristic pattern—strong advance, measured consolidation, and healthy volume—often precedes the next leg higher, especially in anticipation of major clinical or regulatory catalysts.

Fundamental Analysis

Growth, Profitability, and Strategic Position

While Summit has yet to achieve profitability (EPS: -$0.34 in the trailing twelve months), its fundamentals are robust for a late-stage biotech:

• Cash Position: $361.3 million gives Summit tactical flexibility and risk mitigation, providing sufficient runway for its pivotal trials and upcoming commercial efforts.
• Operational Focus: R&D investment remains disciplined and accretive, with $51.2 million spent in Q1 2025. General and Administrative expenses are well-contained, reflecting prudent stewardship.
• Valuation: The absence of a P/E ratio is typical for clinical-stage biotechs; however, Summit’s $18.31 billion market cap is increasingly justified by validated clinical milestones, strategic partnerships, and pipeline depth. The P/B ratio (53.17) is high, reflecting intangible value and anticipated future revenue streams—a common feature for leaders at this inflection point.

Structural Strengths and Future-Proofing

Summit’s primary asset, ivonescimab, is at the vanguard of oncology innovation—a bispecific antibody (PD-1 and VEGF blockade) that harnesses the success of checkpoint inhibition while addressing resistance and tolerability challenges. Key differentiators include:

• Clinical Validation: Direct head-to-head superiority over leading PD-1 inhibitors in high-volume NSCLC indications.
• Pipeline Optionality: Ongoing HARMONi trials across mutational subsets and the expansion into additional solid tumor types provide a platform for long-term revenue diversity.
• Leadership: CEO Robert LaCaze’s appointment early 2025—drawing on experience from Bayer and Bristol-Myers Squibb—brings commercial savvy and a record of successful oncology launches.

Summit also benefits from the high-conviction ownership of insiders (84.31%), reinforcing strategic alignment between management and shareholders, and limiting speculative excess relative to more widely held development-stage names.

Volume and Liquidity

Trading Dynamics and Investor Confidence

SMMT’s recent trading volumes, regularly topping 4 million shares per day, reflect deep liquidity and institutional engagement. This is a marked advantage for Singapore market participants seeking to enter or scale positions without distorting the price. The float (116.18 million shares) is relatively modest given insider holdings, introducing a dynamic where positive news flow can produce amplified upward moves.

Elevated short interest (25.09 million shares or 21.51% of float) further sets the stage for potential short squeezes—an element that has historically catalysed rapid, opportunistic price acceleration, especially in the biotech sector when coupled with strong news or data.

Catalysts and Positive Outlook

Upcoming Data and Strategic Milestones

Summit stands at the threshold of several significant value-unlocking events:

• Mid-2025: Topline results from the HARMONi Phase III trial—success would likely transform Summit from an aspirational story to a frontrunner in global oncology therapeutics.
• Major Medical Conference: Full presentation of the HARMONi-6 results, providing granular efficacy and safety data to the broader clinical community.
• Expanded Indications: New trial initiations at Tier 1 research centers signal potential for ivonescimab’s application in tumors beyond NSCLC, opening up substantial addressable market expansion.
• International Commercialization: The strong China launch platform, supplemented by strategic partnerships in the US and Europe, could enable rapid revenue ramp and global scale.

The sectoral context also supports optimism. With regulators worldwide accelerating approvals for breakthrough oncology products, and M&A activity in biotech re-accelerating, Summit appears ideally positioned at the nexus of innovation and investable secular trends.

Investment Strategies

Entry Logic Across Time Horizons

• Short-Term: Elevated volume, high short interest, and imminent data releases create opportunities for tactical positioning; any retracement toward the 50-day moving average ($21.70) may represent a favorable risk-adjusted entry for active traders.
• Medium-Term: The run-up to the HARMONi topline results—coupled with further clinical presentations—offers strong catalysts for upward re-rating of the stock, especially should data confirm or exceed current expectations.
• Long-Term: For investors focused on structural growth, Summit’s innovative asset portfolio, seasoned management, and emerging commercial trajectory offer a compelling case for inclusion as a core biotech holding. The company’s strategic execution, combined with maturing partnerships, lays the groundwork for sustainable value creation well into the next decade.

Notably, the stock’s technical consolidation after its recent run, coupled with powerful upcoming catalysts, suggests SMMT may be entering a renewed bullish phase—one that rewards conviction and a disciplined, thesis-driven approach.

Is it the Right Time to Buy Summit Therapeutics?

Summit Therapeutics presents a rare convergence of strengths: validated late-stage clinical assets, a fortified cash position, landmark regulatory wins, and management built for commercial execution. Its robust technical momentum, high institutional interest, and clear path to near-term catalysts reinforce the view that current valuation levels seem to represent an excellent opportunity for strategic, growth-oriented investors.

While conscious of the sector’s inherent volatility—and the customary risks associated with a clinical-stage biotech—Summit’s fundamentals and pipeline progression justify renewed interest from market participants considering allocation to high-upside healthcare innovation. Should ongoing trials continue to meet or exceed expectations, the stock may not only sustain its recent gains but potentially enter a new phase of acceleration as a first-in-class oncology platform play.

In summary, Summit Therapeutics stands out as a biotech growth story with the scientific foundation, operational rigor, and upcoming catalysts to merit serious attention. For investors searching for outsized opportunity at the frontier of medical innovation, the current backdrop suggests that Summit’s risk/reward profile is exceptionally well-timed for consideration within a diversified technology or healthcare portfolio.

How to buy Summit Therapeutics stock in Singapore?

Buying Summit Therapeutics (SMMT) shares online is a straightforward and secure process for investors in Singapore, especially when using a licensed broker regulated by the MAS or international authorities. Retail investors typically use two main approaches: spot (cash) buying, where you own the actual shares, and CFD (Contract for Difference) trading, which allows you to speculate on price movements with leverage, without owning the shares. Both methods are accessible online with just a few steps, and your capital is well-protected through regulated platforms. To help you choose, you’ll find a broker comparison further down this page.

Spot buying

A cash purchase means buying actual Summit Therapeutics shares on the NASDAQ, giving you part-ownership of the company, voting rights, and direct exposure to stock performance. Typical Singapore brokerages charge a fixed commission per order, often around SGD $5–$10 (or about USD $5–$8) for US stocks. For example, if the Summit Therapeutics share price is $24.65 USD, a $1,000 USD stake (approx. SGD $1,350) will let you buy around 40 shares. Including a standard brokerage fee of $5, your total outlay is about $1,005.

Example scenario

Gain scenario:
If the share price rises by 10% to $27.12, the value of your 40 shares becomes $1,084.80.
Result: +$100 gross gain (approx. +10%), demonstrating the growth potential with direct stock ownership.

Trading via CFD

CFDs (Contracts for Difference) let you trade Summit Therapeutics stock price movements without owning the actual shares. With a CFD, you can use leverage to amplify your exposure—for example, with 5x leverage, a $1,000 USD deposit gives you exposure to $5,000 worth of SMMT shares. CFD trading typically involves a spread (the difference between buy/sell prices) and overnight financing costs if you hold positions beyond a day. Suppose you invest $1,000 USD with 5x leverage; your market exposure is $5,000.

Example scenario

Gain scenario:
If SMMT rises by 8%, your position gains 8% × 5 = 40%.
Result: +$400 gain on your original $1,000 (excluding spreads and overnight fees), showing the power—and risk—of leverage in CFD trading.

Final advice

Before investing in Summit Therapeutics, it’s essential to carefully compare brokers’ fees, trading conditions, and consumer protections. Your choice between purchasing shares outright or trading via CFDs will depend on your investment goals, experience, and risk appetite. For a simple comparison of the most competitive brokers in Singapore, see the dedicated table further down the page. Choose the approach that best fits your objectives and remember to invest responsibly.

Our 7 tips for buying Summit Therapeutics stock

The latest news about Summit Therapeutics

Summit Therapeutics stock remains strong after successful Phase III trial results for ivonescimab in NSCLC. In the past week, the market has maintained a robust outlook on Summit Therapeutics Inc. following the confirmation that the HARMONi-6 Phase III clinical trial for its flagship bispecific antibody, ivonescimab, in combination with chemotherapy, achieved its primary endpoint in patients with squamous non-small cell lung cancer (NSCLC). These results not only further validate the company’s novel dual mechanism of action, but also reinforce growing confidence across the global oncology community, a sentiment that is reflected in the stock’s continued resilience around $24.65 despite a minor weekly dip of -0.08%. For Singapore-based analysts and investors, these outcomes emphasize Summit’s capacity to deliver innovative solutions to oncology—a therapeutic area of acute local relevance given Singapore’s rising cancer burden and the demand from local healthcare providers for advanced targeted therapies.

Ivonescimab achieves second regulatory approval in China, strengthening its international commercial profile. On April 25, 2025, China’s National Medical Products Administration (NMPA) granted a second indication approval for ivonescimab based on positive outcomes from the HARMONi-2 trial. This expanded regulatory success is particularly significant for markets like Singapore, where regulatory convergence with China on oncology product assessments is growing and pharmaceutical imports from China are increasing. The accelerated acceptance and multi-indication approval of ivonescimab in Asia’s largest healthcare market elevates its credibility and potential for eventual regulatory filings in Singapore and other Southeast Asian jurisdictions, thereby supporting Summit’s strategic regional growth ambitions.

Summit Therapeutics further tightens links with top global cancer centers and pharmaceutical leaders. Recent collaborations include ongoing clinical trial partnerships with prestigious medical institutions such as MD Anderson Cancer Center, Memorial Sloan Kettering, and Dana Farber, as well as a notable alliance with Pfizer to explore ivonescimab’s efficacy in combination with Pfizer’s antibody drug conjugates. The global nature of these partnerships enhances the company’s clinical footprint and opens pathways for knowledge and technology transfer, benefiting the highly internationalized Singapore healthcare sector, which keeps a close watch on developments with major US and European cancer centers for pipeline opportunities and clinical best practices.

Technical performance signals sustained bullish momentum as the stock trades above key moving averages. Currently, SMMT trades well above its 50-day and 200-day moving averages, having shown a 48% price surge over the last month and maintaining a year-to-date gain of 38%. Technical indicators reveal a bullish bias with the RSI entering overbought territory, highlighting the stock’s positive momentum. For sophisticated investors in Singapore who frequently employ technical analysis for high-growth, mid-cap biopharma stocks, these signals confirm continued market conviction while cautioning that profit-taking and short-term volatility may arise given the stock’s overbought condition.

Analyst consensus points to substantial upside potential with positive sentiment driven by clinical and strategic milestones. Wall Street’s average 12-month price target of $37.32 suggests a possible 51% upside from current levels, with consensus anchored in progressing clinical data, robust strategic alliances, and the company’s expanding cash reserves of $361 million to sustain operations through major near-term catalysts such as upcoming HARMONi trial results. For Singapore investors seeking growth-oriented healthcare exposure outside the local market, Summit Therapeutics offers a compelling opportunity backed by recent clinical success, expanding global partnerships, and the promise of first-in-class oncology therapies in markets acutely relevant to the Asia-Pacific region.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.